High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial
Kasper M Petersen, Søren Bøgevig, Troels Riis, Niklas W Andersson, Kim P Dalhoff, Jens J Holst, Filip K Knop, Jens Faber, Tonny S Petersen, Mikkel B Christensen, Kasper M Petersen, Søren Bøgevig, Troels Riis, Niklas W Andersson, Kim P Dalhoff, Jens J Holst, Filip K Knop, Jens Faber, Tonny S Petersen, Mikkel B Christensen
Abstract
Background Intravenous high-dose glucagon is a recommended antidote against beta-blocker poisonings, but clinical effects are unclear. We therefore investigated hemodynamic effects and safety of high-dose glucagon with and without concomitant beta-blockade. Methods and Results In a randomized crossover study, 10 healthy men received combinations of esmolol (1.25 mg/kg bolus+0.75 mg/kg/min infusion), glucagon (50 µg/kg), and identical volumes of saline placebo on 5 separate days in random order (saline+saline; esmolol+saline; esmolol+glucagon bolus; saline+glucagon infusion; saline+glucagon bolus). On individual days, esmolol/saline was infused from -15 to 30 minutes. Glucagon/saline was administered from 0 minutes as a 2-minute intravenous bolus or as a 30-minute infusion (same total glucagon dose). End points were hemodynamic and adverse effects of glucagon compared with saline. Compared with saline, glucagon bolus increased mean heart rate by 13.0 beats per minute (95% CI, 8.0-18.0; P<0.001), systolic blood pressure by 15.6 mm Hg (95% CI, 8.0-23.2; P=0.002), diastolic blood pressure by 9.4 mm Hg (95% CI, 6.3-12.6; P<0.001), and cardiac output by 18.0 % (95% CI, 9.7-26.9; P=0.003) at the 5-minute time point on days without beta-blockade. Similar effects of glucagon bolus occurred on days with beta-blockade and between 15 and 30 minutes during infusion. Hemodynamic effects of glucagon thus reflected pharmacologic glucagon plasma concentrations. Glucagon-induced nausea occurred in 80% of participants despite ondansetron pretreatment. Conclusions High-dose glucagon boluses had significant hemodynamic effects regardless of beta-blockade. A glucagon infusion had comparable and apparently longer-lasting effects compared with bolus, indicating that infusion may be preferable to bolus injections. Registration Information URL: https://www.clinicaltrials.gov; Unique identifier: NCT03533179.
Keywords: beta blocker; glucagon; hemodynamics; toxicology.
Conflict of interest statement
None.
Figures
References
- Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med. 1981;304:1518–1524.
- GlucaGen® HypoKit® Official Product Site . Available at . Accessed August 17, 2019.
- Pujadas G, Drucker DJ. Vascular biology of glucagon receptor superfamily peptides: mechanistic and clinical relevance. Endocr Rev. 2016;37:554–583.
- Meidahl Petersen K, Bøgevig S, Holst JJ, Knop FK, Christensen MB. Hemodynamic effects of glucagon – a literature review. J Clin Endocrinol Metab. 2018;103:1804–1812.
- Silva G, Navasa M, Bosch J, Chesta J, Pilar Pizcueta M, Casamitjana R, Rivera F, Rodés J. Hemodynamic effects of glucagon in portal hypertension. Hepatology. 1990;11:668–673.
- Howland MA. A18. Antidotes in depth: glucagon In: Hoffman RS, Lewin NA, Nelson L, Goldfrank LR, Flomenbaum N, eds. Goldfrank’s toxicologic emergencies, 10th ed. New York: McGraw‐Hill Education; 2015:870–873.
- Boyd R, Ghosh A. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic beta blocker overdose. Emerg Med J. 2003;20:266–267.
- Love JN, Sachdeva DK, Bessman ES, Curtis LA, Howell JM. A potential role for glucagon in the treatment of drug‐induced symptomatic bradycardia. Chest. 1998;114:323–326.
- Bailey B. Glucagon in beta‐blocker and calcium channel blocker overdoses: a systematic review. J Toxicol Clin Toxicol. 2003;41:595–602.
- Kerns W. Management of beta‐adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25:309–331. abstract viii.
- World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
- Volz‐Zang C, Eckrich B, Jahn P, Schneidrowski B, Schulte B, Palm D. Esmolol, an ultrashort‐acting, selective beta 1‐adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties. Eur J Clin Pharmacol. 1994;46:399–404.
- Karippacheril J, Ho T. Data acquisition from S/5 GE Datex anesthesia monitor using VSCapture: An open tool. J Anaesthesiol Clin Pharmacol. 2013;29:423.
- Liljestrand G, Zander E. Vergleichende Bestimmungen des Minutenvolumens des Herzens beim Menschen mittels der Stickoxydulmethode und durch Blutdruckmessung. Zeitschrift für die gesamte experimentelle Medizin. 1928;59:105–122.
- Zhang J, Critchley LAH, Huang L. Five algorithms that calculate cardiac output from the arterial waveform: a comparison with Doppler ultrasound. Br J Anaesth. 2015;115:392–402.
- Sample Size . Available at
- Williams E. Experimental designs balanced for the estimation of residual effects of treatments. Aust J Chem. 1949;2:149.
- Hendy GN, Tomlinson S, O’Riordan JL. Impaired responsiveness to the effect of glucagon on plasma adenosine 3′:5′‐cyclic monophosphate in normal man. Eur J Clin Invest. 1977;7:155–160.
- Yao LF, MacLeod KM, McNeill JH. Glucagon‐induced densensitization: correlation between cyclic AMP levels and contractile force. Eur J Pharmacol. 1982;79:147–150.
- Ranganath L, Schaper F, Gama R, Morgan L. Mechanism of glucagon‐induced nausea. Clin Endocrinol (Oxf). 1999;51:260–261.
- Murtagh JG, Binnion PF, Lal S, Hutchison KJ, Fletcher E. Haemodynamic effects of glucagon. Br Heart J. 1970;32:307–315.
- Sélley E, Kun S, Szijártó IA, Kertész M, Wittmann I, Molnár GA. Vasodilator effect of glucagon: receptorial crosstalk among glucagon, GLP‐1, and receptor for glucagon and GLP‐1. Horm Metab Res. 2016;48:476–483.
- Denfeld QE, Habecker BA, Woodward WR. Measurement of plasma norepinephrine and 3,4‐dihydroxyphenylglycol: method development for a translational research study. BMC Res Notes. 2018;11.
- Goldstein DS, McCarty R, Polinsky RJ, Kopin IJ. Relationship between plasma norepinephrine and sympathetic neural activity. Hypertension. 1983;5:552–559.
- Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, Cappola TP, Margulies KB, Drucker DJ. GLP‐1 receptor expression within the human heart. Endocrinology. 2018;159:1570–1584.
- Runge S, Wulff BS, Madsen K, Bräuner‐Osborne H, Knudsen LB. Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol. 2003;138:787–794.
- Pyke C, Heller RS, Kirk RK, Ørskov C, Reedtz‐Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D, Knudsen LB. GLP‐1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–1290.
- Ussher JR, Drucker DJ. Cardiovascular actions of incretin‐based therapies. Circ Res. 2014;114:1788–1803.
- Goldstein DS. Adrenaline and Noradrenaline. In: John Wiley & Sons Ltd, ed. Encyclopedia of Life Sciences. Chichester, UK: John Wiley & Sons, Ltd; 2010. doi:10.1002/9780470015902.a0001401.pub2.
- Reilly CS, Wood M, Koshakji RP, Wood AJ. Ultra‐short‐acting beta‐blockade: a comparison with conventional beta‐blockade. Clin Pharmacol Ther. 1985;38:579–585.
- Lauterbach M. Clinical toxicology of beta‐blocker overdose in adults. Basic Clin Pharmacol Toxicol. 2019;125:178–186.
Source: PubMed